Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of NAFLD with N-acetylcysteine, pioglitazone and metformin
IRCT201309188308N3Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of acetylcysteine, pioglitazone and metformin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Hamadan University of Medical Sciences. Started Nov 2014; status: completed.
02
Drugs
acetylcysteinepioglitazonemetformin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT201309188308N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201309188308N3.